Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ponatinib + mini-hyper-CVD + venetoclax
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This investigational combination regimen is being evaluated in a Phase II clinical trial at the M.D. Anderson Cancer Center for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). The regimen integrates three distinct therapeutic strategies: **ponatinib**, a multi-targeted tyrosine kinase inhibitor that inhibits BCR-ABL and other relevant kinases; **venetoclax**, a selective BCL-2 inhibitor that promotes apoptosis; and **mini-hyper-CVD**, a dose-attenuated chemotherapy backbone. Mini-hyper-CVD consists of cyclophosphamide, vincristine, and dexamethasone alternating with methotrexate and cytarabine. By combining targeted kinase inhibition, apoptotic sensitization, and cytotoxic chemotherapy, the regimen aims to overcome resistance mechanisms and improve complete remission rates in patients with advanced T-ALL.
- Other names
- Ponatinib, Mini-hyper-CVD, and VenetoclaxMini-hyper-CVD plus ponatinib and venetoclaxMini-HCVD-Pon-Ven
02
Targets
Bcl-w (B-cell lymphoma 2-like 2)PDGFRA (Platelet-derived growth factor receptor alpha)BCL2L1 (B-cell lymphoma-extra large protein)BCR-ABL1 (Breakpoint cluster region-Abelson tyrosine-protein kinase 1)VEGFR2 (Vascular endothelial growth factor receptor 2)DHFR (Dihydrofolate reductase)DNA polymerase familyGR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on ponatinib + mini-hyper-CVD + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ponatinib + mini-hyper-CVD + venetoclax.